ABEO Abeona Therapeutics Inc

$ABEO I’m invested in Abeona for years now, lot of downs more than ups. BUT I really recommend you searching for Hayden Zevaskyn treatment on Facebook, not only that this brave little boy got treated a few weeks ago at UTMB as first patient successfully, he will probably count in Q3. I assume we see 8 patients treated and 7 revenue in Q3, the more quarters will pass the more Abeona will grow. This therapy is unique and so life changing. If you are crazy and short, have the courage and watch what you are betting against. We have Zevaskyn, enough cash ~140 million in the bank and future milestones from UX111 + the pipeline. I’m more bullish than ever and love to see the progress. If not this management scale it right than there will be one who can for sure ;-) Not speculating for an BO at the moment but with decreasing MC more likely. PS: If you watched Haydens story and progress, sent him some money rather then buying BS or shorts

$ABEO we’re close the the March low while the company is currently in a much better position than 7 months ago. Buying opportunity here before the next earnings report in Nov.

$ABEO - Daily reminder - to just breathe - let this company do its thing. It is in its first commercial year, its building its centers which is crucial to support possible patients. They already have a secondary revenue stream with $30MIL and royalties moving forward.... Not to mention its a life saving product that no one else has..... Just breathe.... and think 3yrs from now

$ABEO - Wooooo! roller coasting prices.... its going to be crazy soon enough! Remember these few things, Multiple treatment centers, only first year in commercial with a life saving product that no one else has.... That's the story -

$ABEO Digging into potential treatment numbers for Q3: As of last earnings report (8/13), they stated 3 treatments thus far, though 1 won't recognize rev due to being out of spec. Assuming the 3 treatments were Stanford, Lurie, and CHOP. They stated at the time, UTMB has biopsied. FB posts have a family sharing their child's journey with Zevaskyn and going in for a biopsy in early September. Confirmed treatment took place (through the posts) at the end of September. This likely means another patient had already been biopsied and likely treated beforehand, so (+2) from UTMB. So if the other centers did not treat for the remainder of the qtr, that is a 5 treatment floor. Considering Stanford and Lurie alone did 5 treatments in Q2, and were likely 2 out of the 3 treatments as of last earnings, at their current cadence, likely +3-4 treatments to match Q2. I think we are highly likely to be at base 8-9 treatments for Q3. 1/2

$ABEO Small fundamental reminder, alone the UX111 upcoming royalties are between 10-20% from the MC at this moment.

$ABEO "Abeona Therapeutics Inc. (NASDAQ: ABEO) has a net cash position of approximately $126.95 million ($2.22 per share), based on the latest balance sheet data. Balance Sheet Breakdown • Cash & Cash Equivalents: $146.83 million • Total Debt: $19.87 million • Net Cash: $126.95 million • Net Cash Per Share: $2.22 So at the current price investors are paying net of cash $2.47 per share for the entire Zevaskyn franchise and all the other stuff. ABSOLUTELY CRAZY.

$ABEO back in with 16k shares at $4.35 (sold out and got back in for a whole $0.05 less than my original position I sold 100% of) useless and goes to show if you’re happy with your position leave it alone!

$ABEO - New centers and new employee RSU's is the thing to remember - they are building a base to launch off of.....

$ABEO I support James Russell. Let’s get that gupta red dot loser Vish the Fish out of there!

$ABEO Their valuing the company @ 100 million dollars (minus the cash on hand) with 2 approved drugs/Zevaskyn having a market potential of 4 billion incredibly cheap!!!!!! Someone is going buy them out on the cheap imo

$ABEO AI Overview Abeona Therapeutics is targeting a manufacturing capacity of 10 slots (procedures) per month by 2027. • Maximum Targeted Capacity: 10 procedures per month. The company is scaling up its manufacturing capabilities by adding a second production suite to reach this 10-slot monthly goal. • Current Operational Baseline (2026): Production is operating at 6 slots per month, with early Qualified Treatment Centers (QTCs) handling roughly 1 to 2 patients per month. • Financial Break-Even Cadence: Management has stated that the therapy achieves free-cash-flow positivity once it scales to more than 3 patients treated per month. Each authorized treatment center is expected to ultimately maintain a steady cadence of roughly 1 patient per month. NOTE: 10 procedures per month would result in total revenues in 2027 of about $360M at a Gross Margin of about $85% to 90%.

$ABEO Estimated earnings and revenue for Q3 are about 50% better than Q2. So why the weakness?

$ABEO As of the most recent official FINRA bi-monthly short interest report (settlement date September 30, 2026), 16,882,889 shares of Abeona Therapeutics Inc. (ABEO) were sold short. This figure represents an increase of 1,137,791 shares (approximately +7.23%) from the prior report of 15,745,098 shares as of September 15, 2026. The corresponding short interest ratio (days to cover) is 11.57. The most compelling setup would be high short interest (16.88M shrs or 33.30% of the float) + elevated days to cover (11.57 days) + a positive catalyst (more treatments and realized revenue) + rising share price and volume. Waiting...

$ABEO They try so hard 😂 I know watching the charts everyday makes you go nuts but the games played with Abeona are really insane. Short interest published today will be interesting

$ABEO They want your shares folks. They'll eventually try to create some sort of scandal or bad news to frighten you into selling your shares....

$ABEO The price drop today has nothing to do with ABEO individually, but everything to do with a huge drop in the NBI index of which ABEO is a part. It is done a gigantic 200 points or 2.88%. Can't remember it being down that much in any day.

$ABEO My understanding that other institutions are fed up as well and are on board for change.

$ABEO If ABEO has indeed turned the corner and become profitable this is one of the the best value plays in Biotech IMO

$ABEO So assuming Zevaskyn is now profitable the stock should re-rate quite substantially imo Heck its trading for pennies on the dollar